The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis
Open accessAbstract
HER2 is a tyrosine kinase receptor causally involved in cancer. A subgroup of breast cancer patients with particularly poor clinical outcomes expresses a heterogeneous collection of HER2 carboxy-terminal fragments (CTFs). However, since the CTFs lack the extracellular domain that drives dimerization and subsequent activation of full-length HER2, they are in principle expected to be inactive. Here we show that at low expression levels one of these fragments, 611-CTF, activated multiple signaling pathways because of its unanticipated ability to constitutively homodimerize. A transcriptomic analysis revealed that 611-CTF specifically controlled the expression of genes that we found to be correlated with poor prognosis in breast cancer. Among the 611-CTF-regulated genes were several that have previously been linked to metastasis, including those for MET, EPHA2, matrix metalloproteinase 1, interleukin 11, angiopoietin-like 4, and different integrins. It is thought that transgenic mice overexpressing HER2 in the mammary glands develop tumors only after acquisition of activating mutations in the transgene. In contrast, we show that expression of 611-CTF led to development of aggressive and invasive mammary tumors without the need for mutations. These results demonstrate that 611-CTF is a potent oncogene capable of promoting mammary tumor progression and metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 1×
“This result is in agreement with the known ability of HER2 to regulate the expression of genes important for tumor progression ( 43 ).”
ResultSomatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas
Shigematsu, H., Takahashi, T., Nomura, M., Majmudar, K., Suzuki, M., Lee, H., Wistuba, I. I., Fong, K. M., Toyooka, S., Shimizu, N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4235 · Cited by 678 · cited 1×
“In contrast to the situation in TG mice, HER2 is not frequently mutated in samples from human mammary tumors (34).”
ResultBiosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation
Anido, J., Scaltriti, M., Bech Serra, J. J., Josefat, B. S., Rojo Todo, F., Baselga, J., & Arribas, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601191 · Cited by 231
Self-citation
Cited by
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Baselga, J., & Swain, S. M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2656 · Cited by 1,142
Self-citationPotential role of HER2‐overexpressing exosomes in countering trastuzumab‐based therapy
Ciravolo, V., Huber, V., Ghedini, G. C., Venturelli, E., Bianchi, F., Campiglio, M., Morelli, D., Villa, A., Mina, P. D., Menard, S., et al. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22773 · Cited by 514
Circular DNA elements of chromosomal origin are common in healthy human somatic tissue
Møller, H. D., Mohiyuddin, M., Prada-Luengo, I., Sailani, M. R., Halling, J. F., Plomgaard, P., Maretty, L., Hansen, A. J., Snyder, M. P., Pilegaard, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03369-8 · Cited by 414
Georgilis, A., Klotz, S., Hanley, C. J., Herranz, N., Weirich, B., Morancho, B., Leote, A. C., D'Artista, L., Gallage, S., Seehawer, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.007 · Cited by 237
“…This paper N/A pTR-mCMV-copGFP Natarajan et al., 2014 N/A pTR-NF-kB-mCMV-copGFP Natarajan et al., 2014 N/A p95HER2/611 Joaquin Arribas Laboratory; Pedersen et al., 2009 N/A Tet-ON/PTBP1 This paper N/A Tet-ON/EXOC7 This paper N/A pLenti-CMV rtTA3 Addgene w785-1 Software and Algorithms B-score…”
BackgroundInfluentialSelf-citationScaltriti, M., Chandarlapaty, S., Prudkin, L., Aura, C., Jimenez, J., Angelini, P. D., Sánchez, G., Guzman, M., Parra, J. L., Ellis, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3407 · Cited by 151
“To assess the exquisite activity of lapatinib in inhibiting p95HER2-dependent tumor growth, we used an experimental model based on mouse embryonic fibroblasts (MEF) stably transfected with the most active fragment of p95HER2 (611-CTF), produced by alternative initiation of translation starting at methionine 611 of the…”
BackgroundMethodInfluentialSelf-citationRole of ADAM17 in the non-cell autonomous effects of oncogene-induced senescence.
Morancho, B., Martínez-Barriocanal, Á., Villanueva, J., & Arribas, J. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0619-7 · Cited by 13
“Transcripts and secretome analysis were performed as described in [15] and [2], respectively.”
BackgroundMethodSelf-citation
Metadata
- Authors
- Pedersen, K., Angelini, P.-D., Laos, S., Bach-Faig, A., Cunningham, M. P., Ferrer-Ramón, C., Luque-García, A., García-Castillo, J., Parra-Palau, J. L., Scaltriti, M., y Cajal, S. R., Baselga, J., & Arribas, J.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2009-06
- Volume
- 29
- Issue
- 12
- Pages
- 3319-3331
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2104728809
- Cited by
- 186
- References
- 3
- FWCI
- 7.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.